Diagnostic Accuracy of PLA2R Autoantibodies and Glomerular Staining for the Differentiation of Idiopathic and Secondary Membranous Nephropathy: an Updated Meta-analysis

Overview

Journal Sci Rep

Specialty Science

Date 2015 Mar 6

PMID 25740009

Citations 48

Authors

Huanzi Dai

Huhai Zhang

Yani He

Affiliations

Soon will be listed here.

Abstract

The diagnostic performance of M-type phospholipase A2 receptor (PLA2R) autoantibodies and PLA2R glomerular staining in discriminating between idiopathic membranous nephropathy (iMN) and secondary membranous nephropathy (sMN) has not been fully evaluated. We conducted an updated meta-analysis to investigate the accuracy and clinical value of serological anti-PLA2R test and histological PLA2R staining for differentiation iMN from sMN. A total of 19 studies involving 1160 patients were included in this meta-analysis. The overall sensitivity, specificity, diagnostic odds ratio (DOR) and area under the receiver operating characteristic curve (AUROC) of serum anti-PLA2R were 0.68 (95% CI, 0.61-074), 0.97 (95% CI, 0.85-1.00), 73.75 (95% CI, 12.56-432.96) and 0.82 (95% CI, 0.78-0.85), respectively, with substantial heterogeneity (I(2) = 86.42%). Subgroup analyses revealed the study design, publication type, study origin, assay method might account for the heterogeneity. Additionally, the overall sensitivity, specificity, DOR and AUROC of glomerular PLA2R staining were 0.78 (95% CI, 0.72-0.83), 0.91 (95% CI, 0.75-0.97), 34.70 (95% CI, 9.93-121.30) and 0.84 (95% CI, 0.81-0.87), respectively, without heterogeneity (I(2) = 0%). Serological anti-PLA2R testing has diagnostic value, but it must be interpreted in context with patient clinical characteristics and histological PLA2R staining in seronegative patients is recommended.

Citing Articles

Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy.

Vink C, Wetzels J, Logt A Kidney Int Rep. 2024; 9(12):3439-3445.

PMID: 39698354 PMC: 11652067. DOI: 10.1016/j.ekir.2024.08.033.

A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy.

Wang Y, Ma X, Yang X, Bai S, Zang X, Liao L Ren Fail. 2024; 46(2):2409353.

PMID: 39351796 PMC: 11445897. DOI: 10.1080/0886022X.2024.2409353.

Glomerulonephritis during Mycobacterium tuberculosis infection: scoping review.

Forster A, Sabur N, Iqbal A, Vaughan S, Thomson B BMC Nephrol. 2024; 25(1):285.

PMID: 39217294 PMC: 11366146. DOI: 10.1186/s12882-024-03716-6.

Liquid biopsy for non-invasive monitoring of patients with kidney transplants.

Nassar A, Cashman K, Rao S, Dagher M, OBrien C, Afif J Front Transplant. 2024; 2:1148725.

PMID: 38993899 PMC: 11235308. DOI: 10.3389/frtra.2023.1148725.

Combined evaluation of glomerular phospholipase A2 receptor and immunoglobulin G subclass in membranous nephropathy.

Ueki K, Tsuchimoto A, Matsukuma Y, Ataka E, Okamoto H, Tanaka S Clin Kidney J. 2024; 17(6):sfae104.

PMID: 38854426 PMC: 11161704. DOI: 10.1093/ckj/sfae104.

References

Beck Jr L, Bonegio R, Lambeau G, Beck D, Powell D, Cummins T . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11-21. PMC: 2762083. DOI: 10.1056/NEJMoa0810457. View

Qin W, Beck Jr L, Zeng C, Chen Z, Li S, Zuo K . Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011; 22(6):1137-43. PMC: 3103733. DOI: 10.1681/ASN.2010090967. View

Larsen C, Messias N, Silva F, Messias E, Walker P . Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2012; 26(5):709-15. DOI: 10.1038/modpathol.2012.207. View

Oh Y, Yang S, Kim D, Kang S, Kim Y . Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One. 2013; 8(4):e62151. PMC: 3637390. DOI: 10.1371/journal.pone.0062151. View

Kanigicherla D, Gummadova J, Mckenzie E, Roberts S, Harris S, Nikam M . Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013; 83(5):940-8. DOI: 10.1038/ki.2012.486. View

Hoxha E, Kneissler U, Stege G, Zahner G, Thiele I, Panzer U . Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012; 82(7):797-804. DOI: 10.1038/ki.2012.209. View

Ronco P, Debiec H . Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol. 2012; 8(4):203-13. DOI: 10.1038/nrneph.2012.35. View

Dahnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels J . Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta. 2013; 421:213-8. DOI: 10.1016/j.cca.2013.03.015. View

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

11.

Ardalan M, Ghafari A, Hamzavi F, Nasri H, Baradaran B, Majidi J . Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population. J Nephropathol. 2014; 2(4):241-8. PMC: 3891130. DOI: 10.12860/JNP.2013.38. View

12.

Jefferson J, Couser W . Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol. 2003; 23(4):400-5. DOI: 10.1016/s0270-9295(03)00055-x. View

13.

Ponticelli C, Glassock R . Glomerular diseases: membranous nephropathy--a modern view. Clin J Am Soc Nephrol. 2013; 9(3):609-16. PMC: 3944756. DOI: 10.2215/CJN.04160413. View

14.

Hu S, Wang D, Gou W, Lei Q, Ma T, Cheng J . Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis. J Nephrol. 2014; 27(2):111-6. DOI: 10.1007/s40620-014-0042-7. View

15.

Terrier B, Degand N, Guilpain P, Servettaz A, Guillevin L, Mouthon L . Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev. 2007; 6(3):176-82. DOI: 10.1016/j.autrev.2006.10.004. View

16.

Lefaucheur C, Stengel B, Nochy D, Martel P, Hill G, Jacquot C . Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006; 70(8):1510-7. DOI: 10.1038/sj.ki.5001790. View

17.

Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A . Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2012; 7(9):1394-400. PMC: 3430946. DOI: 10.2215/CJN.02170312. View

18.

Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K . An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011; 26(8):2526-32. DOI: 10.1093/ndt/gfr247. View

19.

Hofstra J, Debiec H, Short C, Pelle T, Kleta R, Mathieson P . Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012; 23(10):1735-43. PMC: 3458465. DOI: 10.1681/ASN.2012030242. View

20.

Jhaveri K, Shah H, Calderon K, Campenot E, Radhakrishnan J . Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013; 84(1):34-44. DOI: 10.1038/ki.2012.484. View